Therefore, our results suggested that targeting ILK in the epithelial CRC cells enhanced immune cell cytotoxicity but this depended on the genetic mutation background of the cancer cells, with TP53 mutant cells potentially being more sensitive in absence of ILK to the effector immune NK cells. Here, TP53 is linked to cancer.